TW546145B - Agent for treating visual cell function disorder with macrolide compound as active ingredient - Google Patents
Agent for treating visual cell function disorder with macrolide compound as active ingredient Download PDFInfo
- Publication number
- TW546145B TW546145B TW088122634A TW88122634A TW546145B TW 546145 B TW546145 B TW 546145B TW 088122634 A TW088122634 A TW 088122634A TW 88122634 A TW88122634 A TW 88122634A TW 546145 B TW546145 B TW 546145B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- active ingredient
- agent
- eye
- macrolide compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11393998P | 1998-12-24 | 1998-12-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW546145B true TW546145B (en) | 2003-08-11 |
Family
ID=22352417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW088122634A TW546145B (en) | 1998-12-24 | 1999-12-22 | Agent for treating visual cell function disorder with macrolide compound as active ingredient |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1140134A1 (fr) |
JP (1) | JP2002542150A (fr) |
KR (1) | KR20010099928A (fr) |
CN (1) | CN1224420C (fr) |
AR (1) | AR022017A1 (fr) |
AU (1) | AU781049B2 (fr) |
BR (1) | BR9917113A (fr) |
CA (1) | CA2356382A1 (fr) |
MX (1) | MXPA01006449A (fr) |
NO (1) | NO20013146L (fr) |
NZ (1) | NZ513111A (fr) |
TW (1) | TW546145B (fr) |
WO (1) | WO2000038703A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
WO2003061519A2 (fr) | 2002-01-18 | 2003-07-31 | Massachusetts Eye And Ear Infirmary | Procedes et compositions preservant la viabilite des cellules photoreceptrices de l'oeil |
AU2003272471B2 (en) | 2002-09-18 | 2010-10-07 | Trustees Of The University Of Pennsylvania | Method of inhibiting choroidal neovascularization |
US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
US8637070B2 (en) | 2005-02-09 | 2014-01-28 | Santen Pharmaceutical Co., Ltd. | Rapamycin formulations and methods of their use |
WO2007019427A2 (fr) * | 2005-08-08 | 2007-02-15 | Massachusetts Eye & Ear Infirmary | Methodes et compositions permettant de preserver la viabilite des cellules photoreceptrices |
EP2001438A2 (fr) | 2006-02-09 | 2008-12-17 | Macusight, Inc. | Formulations stables et leurs procedes de preparation et d'utilisation |
ES2563288T3 (es) | 2006-03-23 | 2016-03-14 | Santen Pharmaceutical Co., Ltd | Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular |
US20210338770A1 (en) * | 2018-10-15 | 2021-11-04 | Osaka University | Medicament for improving or preventing symptoms relating to retina and/or light reception and method for screening for substance capable of improving or preventing symptoms relating to retina and/or light reception |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992003049A1 (fr) * | 1990-08-23 | 1992-03-05 | New York University | Procedes et compositions de traitement de maladies induites par les lymphocytes t |
ZA924953B (en) * | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
US5922773A (en) * | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
US5597809A (en) * | 1994-06-23 | 1997-01-28 | Massachusetts Eye & Ear Infirmary | Treatment of optic neuritis |
JP2002511868A (ja) * | 1997-06-30 | 2002-04-16 | アラーガン・セイルズ・インコーポレイテッド | 増殖性硝子体網膜症を治療するためのカルシウム遮断薬 |
CZ287497B6 (cs) * | 1997-12-30 | 2000-12-13 | Galena, A. S. | Topické oční přípravky s imunosupresivními látkami |
US6376517B1 (en) * | 1998-08-14 | 2002-04-23 | Gpi Nil Holdings, Inc. | Pipecolic acid derivatives for vision and memory disorders |
-
1999
- 1999-12-20 BR BR9917113-9A patent/BR9917113A/pt not_active IP Right Cessation
- 1999-12-20 CA CA002356382A patent/CA2356382A1/fr not_active Abandoned
- 1999-12-20 KR KR1020017008060A patent/KR20010099928A/ko not_active Application Discontinuation
- 1999-12-20 AU AU16906/00A patent/AU781049B2/en not_active Ceased
- 1999-12-20 MX MXPA01006449A patent/MXPA01006449A/es unknown
- 1999-12-20 JP JP2000590655A patent/JP2002542150A/ja active Pending
- 1999-12-20 NZ NZ513111A patent/NZ513111A/en unknown
- 1999-12-20 WO PCT/JP1999/007161 patent/WO2000038703A1/fr not_active Application Discontinuation
- 1999-12-20 EP EP99959930A patent/EP1140134A1/fr not_active Withdrawn
- 1999-12-20 CN CNB998162760A patent/CN1224420C/zh not_active Expired - Fee Related
- 1999-12-22 TW TW088122634A patent/TW546145B/zh not_active IP Right Cessation
- 1999-12-23 AR ARP990106748A patent/AR022017A1/es not_active Application Discontinuation
-
2001
- 2001-06-22 NO NO20013146A patent/NO20013146L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU1690600A (en) | 2000-07-31 |
NO20013146L (no) | 2001-08-20 |
NZ513111A (en) | 2003-10-31 |
WO2000038703A1 (fr) | 2000-07-06 |
JP2002542150A (ja) | 2002-12-10 |
EP1140134A1 (fr) | 2001-10-10 |
AU781049B2 (en) | 2005-05-05 |
KR20010099928A (ko) | 2001-11-09 |
NO20013146D0 (no) | 2001-06-22 |
CN1224420C (zh) | 2005-10-26 |
CA2356382A1 (fr) | 2000-07-06 |
AR022017A1 (es) | 2002-09-04 |
BR9917113A (pt) | 2001-10-23 |
MXPA01006449A (es) | 2002-04-24 |
CN1352565A (zh) | 2002-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11433137B2 (en) | Compounds for treating cancer | |
TW546145B (en) | Agent for treating visual cell function disorder with macrolide compound as active ingredient | |
JP2536248B2 (ja) | 水性外用液剤 | |
US20070149548A1 (en) | (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions | |
US20100144858A1 (en) | Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator | |
CZ125198A3 (cs) | Použití derivátu kyseliny pipekolinové a jeho farmaceuticky přijatelných solí pro výrobu léčiva pro ovlivňování neurologické aktivity u zvířete | |
EP1237577A2 (fr) | Administration a travers les muqueuses d'inhibiteurs de la phosphodiesterase dans le traitement de la dyserection | |
JP2011256195A (ja) | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト | |
JPH10513463A (ja) | うっ血性心不全の治療へのカルバゾール化合物の利用 | |
US20030166661A1 (en) | L-arginine and phosphodiesterase (PDE) inhibitor synergism | |
CA2756864A1 (fr) | Agent prophylactique ou therapeutique des retinopathies comprenant un peptide inhibiteur de jnk (c-jun n-terminal kinase), methode de prevention ou de traitement des retinopathies, et utilisation du peptide | |
TWI230066B (en) | A pharmaceutical composition for treating dry eye | |
JPH07504659A (ja) | Ace阻害剤及び利尿剤の併用 | |
US7276514B2 (en) | Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof | |
KR20010013690A (ko) | 동맥 혈전증의 치료와 예방을 위한 조성물과 그 조성물단독 및/또는 혈소판 응집방지제와 결합한 인자 Xa억제제의 사용법 | |
JP2012131829A (ja) | そう痒状態の処置のためのmglur5アンタゴニストの使用 | |
EP1956908A2 (fr) | Compositions et procedes de traitement | |
US6177450B1 (en) | Synergizing combination having an antagonist effect on NKI and NK2 receptors | |
WO2002085372A1 (fr) | Medicaments et trousses medicales | |
MXPA03011847A (es) | Uso de zonisamida en cefalea. | |
Gradin et al. | Cardiovascular effects in the Sprague‐Dawley rat of 8− hydroxy− 2 (di‐N‐propylamino) tetralin, a selective 5− hydroxytryptamine receptor agonist | |
NL8700191A (nl) | Immunosuppressieve middelen, farmaceutische preparaten die ze bevatten en het toepassen van deze middelen. | |
Grunberg | Antiemetic Drugs: Essential Pharmacology | |
AU2006330599B2 (en) | (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions | |
KR20240122521A (ko) | 만성 신장 질환 치료용 알도스테론 신타아제 억제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MM4A | Annulment or lapse of patent due to non-payment of fees |